Last reviewed · How we verify
Pre-randomization Dutasteride
Dutasteride inhibits both type 1 and type 2 5-alpha reductase enzymes, blocking the conversion of testosterone to dihydrotestosterone (DHT).
Dutasteride inhibits both type 1 and type 2 5-alpha reductase enzymes, blocking the conversion of testosterone to dihydrotestosterone (DHT). Used for Benign prostatic hyperplasia (BPH) with lower urinary tract symptoms, Male pattern hair loss (androgenetic alopecia).
At a glance
| Generic name | Pre-randomization Dutasteride |
|---|---|
| Sponsor | Siami, Paul F., M.D. |
| Drug class | 5-alpha reductase inhibitor |
| Target | 5-alpha reductase (type 1 and type 2) |
| Modality | Small molecule |
| Therapeutic area | Urology |
| Phase | FDA-approved |
Mechanism of action
By inhibiting 5-alpha reductase, dutasteride reduces DHT levels in the prostate and serum. This leads to shrinkage of the prostate gland and improved urinary flow in men with benign prostatic hyperplasia. The dual inhibition of both isoforms makes it more potent than finasteride, which only inhibits type 2 reductase.
Approved indications
- Benign prostatic hyperplasia (BPH) with lower urinary tract symptoms
- Male pattern hair loss (androgenetic alopecia)
Common side effects
- Erectile dysfunction
- Decreased libido
- Ejaculation disorder
- Gynecomastia
- Breast tenderness
Key clinical trials
- A Study To Compare Giving AVODART And FLOMAX Together Or In A Combination Capsule In The Fed And Fasted State (PHASE1)
- A Clinical Trial Comparing Laser TURP With and Without Dutasteride. (PHASE3)
- Dutasteride With Tolterodine ER or Placebo to Treat Lower Urinary Tract Symptoms (LUTS) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |